These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 7707514

  • 1. Transcriptional activity of core binding factor-alpha (AML1) and beta subunits on murine leukemia virus enhancer cores.
    Zaiman AL, Lewis AF, Crute BE, Speck NA, Lenz J.
    J Virol; 1995 May; 69(5):2898-906. PubMed ID: 7707514
    [Abstract] [Full Text] [Related]

  • 2. Transcriptional activation of a retrovirus enhancer by CBF (AML1) requires a second factor: evidence for cooperativity with c-Myb.
    Zaiman AL, Lenz J.
    J Virol; 1996 Aug; 70(8):5618-29. PubMed ID: 8764076
    [Abstract] [Full Text] [Related]

  • 3. Stability of AML1 (core) site enhancer mutations in T lymphomas induced by attenuated SL3-3 murine leukemia virus mutants.
    Amtoft HW, Sørensen AB, Bareil C, Schmidt J, Luz A, Pedersen FS.
    J Virol; 1997 Jul; 71(7):5080-7. PubMed ID: 9188573
    [Abstract] [Full Text] [Related]

  • 4. CBF, Myb, and Ets binding sites are important for activity of the core I element of the murine retrovirus SL3-3 in T lymphocytes.
    Zaiman AL, Nieves A, Lenz J.
    J Virol; 1998 Apr; 72(4):3129-37. PubMed ID: 9525638
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo.
    Ethelberg S, Lovmand J, Schmidt J, Luz A, Pedersen FS.
    J Virol; 1997 Oct; 71(10):7273-80. PubMed ID: 9311802
    [Abstract] [Full Text] [Related]

  • 7. Transactivation of the Moloney murine leukemia virus and T-cell receptor beta-chain enhancers by cbf and ets requires intact binding sites for both proteins.
    Sun W, Graves BJ, Speck NA.
    J Virol; 1995 Aug; 69(8):4941-9. PubMed ID: 7609063
    [Abstract] [Full Text] [Related]

  • 8. Selection of reversions and suppressors of a mutation in the CBF binding site of a lymphomagenic retrovirus.
    Martiney MJ, Rulli K, Beaty R, Levy LS, Lenz J.
    J Virol; 1999 Sep; 73(9):7599-606. PubMed ID: 10438850
    [Abstract] [Full Text] [Related]

  • 9. Suppressor mutations within the core binding factor (CBF/AML1) binding site of a T-cell lymphomagenic retrovirus.
    Martiney MJ, Levy LS, Lenz J.
    J Virol; 1999 Mar; 73(3):2143-52. PubMed ID: 9971797
    [Abstract] [Full Text] [Related]

  • 10. Mutation of all Runx (AML1/core) sites in the enhancer of T-lymphomagenic SL3-3 murine leukemia virus unmasks a significant potential for myeloid leukemia induction and favors enhancer evolution toward induction of other disease patterns.
    Sørensen KD, Quintanilla-Martinez L, Kunder S, Schmidt J, Pedersen FS.
    J Virol; 2004 Dec; 78(23):13216-31. PubMed ID: 15542674
    [Abstract] [Full Text] [Related]

  • 11. PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2 beta/CBF beta proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells.
    Nuchprayoon I, Meyers S, Scott LM, Suzow J, Hiebert S, Friedman AD.
    Mol Cell Biol; 1994 Aug; 14(8):5558-68. PubMed ID: 8035830
    [Abstract] [Full Text] [Related]

  • 12. Identification of the SL3-3 virus enhancer core as a T-lymphoma cell-specific element.
    Boral AL, Okenquist SA, Lenz J.
    J Virol; 1989 Jan; 63(1):76-84. PubMed ID: 2535754
    [Abstract] [Full Text] [Related]

  • 13. Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor.
    Wang S, Wang Q, Crute BE, Melnikova IN, Keller SR, Speck NA.
    Mol Cell Biol; 1993 Jun; 13(6):3324-39. PubMed ID: 8497254
    [Abstract] [Full Text] [Related]

  • 14. Differences in activities of murine retroviral long terminal repeats in cytotoxic T lymphocytes and T-lymphoma cells.
    LoSardo JE, Cupelli LA, Short MK, Berman JW, Lenz J.
    J Virol; 1989 Mar; 63(3):1087-94. PubMed ID: 2644446
    [Abstract] [Full Text] [Related]

  • 15. Increased induction of osteopetrosis, but unaltered lymphomagenicity, by murine leukemia virus SL3-3 after mutation of a nuclear factor 1 site in the enhancer.
    Ethelberg S, Tzschaschel BD, Luz A, Diaz-Cano SJ, Pedersen FS, Schmidt J.
    J Virol; 1999 Dec; 73(12):10406-15. PubMed ID: 10559359
    [Abstract] [Full Text] [Related]

  • 16. B-Cell lymphoma induction by akv murine leukemia viruses harboring one or both copies of the tandem repeat in the U3 enhancer.
    Lovmand J, Sorensen AB, Schmidt J, Ostergaard M, Luz A, Pedersen FS.
    J Virol; 1998 Jul; 72(7):5745-56. PubMed ID: 9621033
    [Abstract] [Full Text] [Related]

  • 17. SL3-3 enhancer factor 1 transcriptional activators are required for tumor formation by SL3-3 murine leukemia virus.
    Hallberg B, Schmidt J, Luz A, Pedersen FS, Grundström T.
    J Virol; 1991 Aug; 65(8):4177-81. PubMed ID: 1649324
    [Abstract] [Full Text] [Related]

  • 18. Relative importance of elements within the SL3-3 virus enhancer for T-cell specificity.
    LoSardo JE, Boral AL, Lenz J.
    J Virol; 1990 Apr; 64(4):1756-63. PubMed ID: 2157056
    [Abstract] [Full Text] [Related]

  • 19. Various modes of basic helix-loop-helix protein-mediated regulation of murine leukemia virus transcription in lymphoid cell lines.
    Nielsen AL, Nørby PL, Pedersen FS, Jørgensen P.
    J Virol; 1996 Sep; 70(9):5893-901. PubMed ID: 8709209
    [Abstract] [Full Text] [Related]

  • 20. Regulatory elements within the murine leukemia virus enhancer regions mediate glucocorticoid responsiveness.
    Celander D, Hsu BL, Haseltine WA.
    J Virol; 1988 Apr; 62(4):1314-22. PubMed ID: 2831392
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.